Copper overload within the body may lead to cancer, neurodegenerative diseases, inflammation or fibrosis, among others. Copper chelation is an effective strategy to counteract this potential overload; mitochondria play an important role, as they are the main copper-using organelles in the cells. Copper chelators have been developed, but they have shown some undesired off-target effects and low specificity, which suggests the need for new therapies in the field.
Pinnacle Medicines Inc. secured $89 million in a series B financing, bringing the total raised by the company to $134 million. The round was co-led by LAV and Foresite Capital.
Biolojic Design Ltd. has earned an additional milestone payment from its collaboration partner, Teva Pharmaceutical Industries Ltd., for TEV‘325 (TEV-56308, formerly BD-9), a multibody targeting IL-13 and thymic stromal lymphopoietin (TSLP) for autoimmune disease
Pulmonary fibrosis (PF) is a fatal lung disease characterized by excessive deposition of extracellular matrix proteins in the lung interstitium due to excessive fibroblast activation, which leads to tissue scarring and potential respiratory failure. Chinese researchers have published results of their investigations into circular RNAs and the pathogenesis of PF.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has disclosed crystalline forms of phosphodiesterase PDE4B2 inhibitors. They are reported to be useful for the treatment of chronic obstructive pulmonary disease, interstitial lung diseases and asthma.
CF Pharmtech Inc. has announced IND approval by China’s National Medical Products Administration (NMPA) for ICF-001, a long-acting inhalation powder candidate for the treatment of pulmonary hypertension and related severe pulmonary diseases.
The activation of mast cells in the lungs and skin is involved in diseases such as asthma and chronic spontaneous urticaria, where the KIT receptor tyrosine kinase is a key regulator of mast cell function.
Baseimmune Ltd. has announced its strategic expansion into fibrosis, with a new fibrosis-focused pipeline led by a program for idiopathic pulmonary fibrosis (IPF).
Researchers at Shenyang Pharmaceutical University reported the discovery and preclinical evaluation of a PDE4 inhibitor as a potential treatment for chronic obstructive pulmonary disease.
Antiverse Ltd. has announced the close of a $9.3 million series A financing. The funding will support expansion of the company’s proprietary AI antibody design platform, accelerate development of its internal therapeutic pipeline, and advance lead antibody programs toward in vivo efficacy studies.
RSS
